Gilead Science's Biktarvy dominated the AIDS tx market around the world, including Korea, two years after its launch. Biktarvy consists of Bictegravir Sodium, Emtricitabine, and Tenofovir Alafenamide Fumarate as Gilead's HIV treatment. Compared to conventional treatments, the effectiveness and safety are improved, the expression rate of resistance is low, the pill size is small, and it can be administered regardless of meal. After obtaining approval from the MFDS in January 2019, Biktarvy entered the market in earnest by applying benefit in July of the same year.

According to IQVIA, a pharmaceutical market research firm, Biktarvy's sales increased to 4.6 billion won in the first quarter of its launch.